$18.60
0.11[0.59%]
At close: Apr 23
$18.60
0[0.00%]
After Hours: 4:20PM EDT
Myriad Genetics
(NASDAQ:MYGN)Myriad Genetics Stock (NASDAQ:MYGN), Analyst Ratings, Price Targets, Predictions
Myriad Genetics Inc has a consensus price target of $20.78, established from looking at the 25 latest analyst ratings. The last 3 analyst ratings were released from Goldman Sachs, Goldman Sachs, and Piper Sandler on January 30, 2024, January 29, 2024, and December 21, 2023. With an average price target of $28.33 between Goldman Sachs, Goldman Sachs, and Piper Sandler, there's an implied 52.33% upside for Myriad Genetics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Goldman Sachs
Piper Sandler
Wells Fargo
Guggenheim
Wolfe Research
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Myriad Genetics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 01/30/2024 | MYGN | Buy Now | Myriad Genetics | $18.60 | 66.67% | Goldman Sachs | Matthew Sykes | $28 → $31 | Maintains | Buy | Get Alert |
| 01/29/2024 | MYGN | Buy Now | Myriad Genetics | $18.60 | 66.67% | Goldman Sachs | Matthew Sykes | $28 → $31 | Maintains | Buy | Get Alert |
| 12/21/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 23.66% | Piper Sandler | John Peterson | → $23 | Initiates | → Neutral | Get Alert |
| 12/19/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 7.53% | Wells Fargo | Timothy Daley | → $20 | Initiates | → Equal-Weight | Get Alert |
| 12/14/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 23.66% | Guggenheim | Subbu Nambi | → $23 | Initiates | → Buy | Get Alert |
| 12/13/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | — | Wolfe Research | Doug Schenkel | — | Initiates | → Outperform | Get Alert |
| 11/07/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | -24.73% | JP Morgan | Rachel Vatnsdal | $17 → $14 | Maintains | Underweight | Get Alert |
| 08/07/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | -8.6% | JP Morgan | Rachel Vatnsdal | $18 → $17 | Maintains | Underweight | Get Alert |
| 07/24/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 50.54% | Goldman Sachs | Matthew Sykes | $25 → $28 | Maintains | Buy | Get Alert |
| 07/21/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 50.54% | Goldman Sachs | Matthew Sykes | $25 → $28 | Maintains | Buy | Get Alert |
| 05/24/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 34.41% | Goldman Sachs | Matthew Sykes | $18 → $25 | Maintains | Buy | Get Alert |
| 05/23/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 34.41% | Goldman Sachs | Matthew Sykes | $18 → $25 | Upgrade | Sell → Buy | Get Alert |
| 05/04/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | -3.23% | Goldman Sachs | Matthew Sykes | $20 → $18 | Maintains | Sell | Get Alert |
| 05/04/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 29.03% | Stephens & Co. | Mason Carrico | → $24 | Reiterates | → Equal-Weight | Get Alert |
| 03/06/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 29.03% | Stephens & Co. | Mason Carrico | $17 → $24 | Maintains | Equal-Weight | Get Alert |
| 03/03/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 45.16% | Raymond James | Andrew Cooper | $25 → $27 | Maintains | Outperform | Get Alert |
| 01/18/2023 | MYGN | Buy Now | Myriad Genetics | $18.60 | 34.41% | Raymond James | Andrew Cooper | → $25 | Upgrade | Market Perform → Outperform | Get Alert |
| 11/02/2022 | MYGN | Buy Now | Myriad Genetics | $18.60 | 34.41% | SVB Leerink | Puneet Souda | $27 → $25 | Maintains | Market Perform | Get Alert |
| 10/06/2022 | MYGN | Buy Now | Myriad Genetics | $18.60 | 18.28% | Stephens & Co. | Mason Carrico | → $22 | Initiates | → Equal-Weight | Get Alert |
FAQ
What is the target price for Myriad Genetics (MYGN)?
The latest price target for Myriad Genetics (NASDAQ: MYGN) was reported by Goldman Sachs on January 30, 2024. The analyst firm set a price target for $31.00 expecting MYGN to rise to within 12 months (a possible 66.67% upside). 14 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Myriad Genetics (MYGN)?
The latest analyst rating for Myriad Genetics (NASDAQ: MYGN) was provided by Goldman Sachs, and Myriad Genetics maintained their buy rating.
When was the last upgrade for Myriad Genetics (MYGN)?
The last upgrade for Myriad Genetics Inc happened on May 23, 2023 when Goldman Sachs raised their price target to $25. Goldman Sachs previously had a sell for Myriad Genetics Inc.
When was the last downgrade for Myriad Genetics (MYGN)?
There is no last downgrade for Myriad Genetics.
When is the next analyst rating going to be posted or updated for Myriad Genetics (MYGN)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Myriad Genetics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Myriad Genetics was filed on January 30, 2024 so you should expect the next rating to be made available sometime around January 30, 2025.
Is the Analyst Rating Myriad Genetics (MYGN) correct?
While ratings are subjective and will change, the latest Myriad Genetics (MYGN) rating was a maintained with a price target of $28.00 to $31.00. The current price Myriad Genetics (MYGN) is trading at is $18.60, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.